Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company developing cancer immunotherapies using its proprietary INTASYL small interfering RNA (siRNA) gene silencing technology. INTASYL enables self-delivering RNAi compounds without specialized formulations or delivery systems. Lead compound PH-762 targets PD-1 and is in a Phase 1b clinical trial for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. PH-894 targets BRD4 with a dual mode of action. The company operates as a single segment focused on immuno-oncology.
Q2 FY2026 — expected 2026-09-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-05 | 2025-12-31 | 0001437749-26-007078 | EDGAR | 47K words |
| 2025-03-31 | 2024-12-31 | 0001683168-25-002134 | EDGAR | 50K words |
| 2024-04-01 | 2023-12-31 | 0001683168-24-002021 | EDGAR | 44K words |
| 2023-03-22 | 2022-12-31 | 0001683168-23-001678 | EDGAR | 46K words |
| 2022-03-22 | 2021-12-31 | 0001683168-22-001833 | EDGAR | — |
| 2021-03-25 | 2020-12-31 | 0001683168-21-001062 | EDGAR | — |
| 2020-03-26 | 2019-12-31 | 0001683168-20-000969 | EDGAR | — |
| 2019-03-27 | 2018-12-31 | 0001683168-19-000795 | EDGAR | — |
| 2018-03-26 | 2017-12-31 | 0001193125-18-096053 | EDGAR | — |
| 2017-03-30 | 2016-12-31 | 0001193125-17-102730 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001437749-26-026271 | EDGAR | 15K words |
| 2025-11-13 | 2025-09-30 | 0001437749-25-034857 | EDGAR | 18K words |
| 2025-08-14 | 2025-06-30 | 0001683168-25-006174 | EDGAR | 18K words |
| 2025-05-15 | 2025-03-31 | 0001683168-25-003719 | EDGAR | 16K words |
| 2024-11-14 | 2024-09-30 | 0001683168-24-008120 | EDGAR | 16K words |
| 2024-08-14 | 2024-06-30 | 0001683168-24-005706 | EDGAR | 15K words |
| 2024-05-09 | 2024-03-31 | 0001683168-24-003175 | EDGAR | 12K words |
| 2023-11-09 | 2023-09-30 | 0001683168-23-007809 | EDGAR | 13K words |
| 2023-08-10 | 2023-06-30 | 0001683168-23-005514 | EDGAR | 13K words |
| 2023-05-11 | 2023-03-31 | 0001683168-23-003213 | EDGAR | 11K words |
| 2022-11-10 | 2022-09-30 | 0001683168-22-007528 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001683168-22-005565 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-28 | 0001437749-26-031337 | EDGAR | 1K words |
| 2026-09-14 | 0001437749-26-030236 | EDGAR | 1K words |
| 2026-08-06 | 0001437749-26-026275 | EDGAR | 2K words |
| 2026-07-21 | 0001437749-26-023916 | EDGAR | 1K words |
| 2026-03-30 | 0001437749-26-010164 | EDGAR | 1K words |
| 2026-03-05 | 0001437749-26-007071 | EDGAR | 2K words |
| 2026-02-18 | 0001437749-26-004542 | EDGAR | 1K words |
| 2026-02-10 | 0001437749-26-003575 | EDGAR | 1K words |
| 2026-01-20 | 0001437749-26-001500 | EDGAR | 1K words |
| 2025-12-23 | 0001437749-25-038607 | EDGAR | 1K words |
332 total filings indexed. 300 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001533040 |
| Ticker | PHIO |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.phiopharma.com |
| Listed | 2012-05-10 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/PHIO (~200 tokens, structured JSON with cryptographic provenance)